Table 1.

The rate of change of GFR in male patients with Fabry disease during 12 to 54 mo of ERT with agalsidase alfa

Baseline GFR Range (ml/min per 1.73 m2)Age (yr; Mean ± SD)nTreatment Time (yr; Mean ± SD)Baseline Proteinuria (mg/24 h; Median [Min, Max])aBaseline GFR (ml/min per 1.73 m2; Mean ± SD)Rate of Change in GFR (ml/min per 1.73 m2/yr; Mean ± SD)
≥13535.0 ± 8.881.2 ± 0.21236 (n = 1)151.9 ± 16.4−24.5 ± 9.0
90 to <13528.5 ± 7.8332.0 ± 1.0207 (6, 912; n = 29)109.6 ± 13.4−2.2 ± 9.3
60 to <9036.5 ± 7.8362.2 ± 1.2500 (611, 5382; n = 36)78.1 ± 8.4−3.2 ± 6.7
30 to <6041.3 ± 7.8142.1 ± 0.91192 (228, 7980; n = 13)50.1 ± 8.2−2.9 ± 11.8
15 to <3041.5 ± 6.421.010,545 (n = 1)26.7−9.5
Totalb34.4 ± 9.0852.1 ± 1.1388 (6, 10,545; n = 79)84.5 ± 25.5−2.9 ± 8.7
  • a n = the number of patients who had quantitative assessment of baseline proteinuria.

  • b Excluding patients with a baseline GFR >135 ml/min per 1.73 m2.